Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival

Breast Cancer Research

Volumn 11, Issue 6, 2009, Pages

  Pai, Vaibhav P ^a,b   Marshall, Aaron M ^a   Hernandez, Laura L ^a   Buckley, Arthur R ^a   Horseman, Nelson D ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN; SEROTONIN RECEPTOR; TRYPTOPHAN HYDROXYLASE; TPH1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; SEROTONIN RELEASE; SIGNAL TRANSDUCTION; BIOSYNTHESIS; BREAST TUMOR; CELL GROWTH; EPITHELIUM CELL; FEMALE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL SURVIVAL; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTORS, SEROTONIN; SEROTONIN; SIGNAL TRANSDUCTION; TRYPTOPHAN HYDROXYLASE;

EID: 77954600574     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2448     Document Type: Article

References (92)

1. Polyak K. Breast cancer: origins and evolution. J Clin Invest 2007, 117:3155-3163. 10.1172/JCI33295, 17975657, 2045618.
2. Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet 2009, 25:30-38. 10.1016/j.tig.2008.10.012, 19054589.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
4. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231. 10.1016/j.ccr.2009.01.027, 19249680.
5. Matsuda M, Imaoka T, Vomachka AJ, Gudelsky GA, Hou Z, Mistry M, Bailey JP, Nieport KM, Walther DJ, Bader M, Horseman ND. Serotonin regulates mammary gland development via an autocrine-paracrine loop. Dev Cell 2004, 6:193-203. 10.1016/S1534-5807(04)00022-X, 14960274.
6. Stull MA, Pai V, Vomachka AJ, Marshall AM, Jacob GA, Horseman ND. Mammary gland homeostasis employs serotonergic regulation of epithelial tight junctions. Proc Natl Acad Sci USA 2007, 104:16708-16713. 10.1073/pnas.0708136104, 2034263, 17940054.
7. Pai VP, Horseman ND. Biphasic Regulation of Mammary Epithelial Resistance by Serotonin through Activation of Multiple Pathways. J Biol Chem 2008, 283:30901-30910. 10.1074/jbc.M802476200, 2576527, 18782769.
8. Hernandez LL, Stiening CM, Wheelock JB, Baumgard LH, Parkhurst AM, Collier RJ. Evaluation of serotonin as a feedback inhibitor of lactation in the bovine. J Dairy Sci 2008, 91:1834-1844. 10.3168/jds.2007-0766, 18420614.
9. Hadsell DL, Parlow AF, Torres D, George J, Olea W. Enhancement of maternal lactation performance during prolonged lactation in the mouse by mouse GH and long-R3-IGF-I is linked to changes in mammary signaling and gene expression. J Endocrinol 2008, 198:61-70. 10.1677/JOE-07-0556, 18577570.
10. Park M, Kang K, Park S, Back K. Conversion of 5-hydroxytryptophan into serotonin by tryptophan decarboxylase in plants, Escherichia coli, and yeast. Biosci Biotechnol Biochem 2008, 72:2456-2458. 10.1271/bbb.80220, 18776677.
11. Callera G, Tostes R, Savoia C, Muscara MN, Touyz RM. Vasoactive peptides in cardiovascular (patho)physiology. Expert Rev Cardiovasc Ther 2007, 5:531-552. 10.1586/14779072.5.3.531, 17489676.
12. Mohammad-Zadeh LF, Moses L, Gwaltney-Brant SM. Serotonin: a review. J Vet Pharmacol Ther 2008, 31:187-199. 10.1111/j.1365-2885.2008.00944.x, 18471139.
13. Crowell MD, Wessinger SB. 5-HT and the brain-gut axis: opportunities for pharmacologic intervention. Expert Opin Investig Drugs 2007, 16:761-765. 10.1517/13543784.16.6.761, 17501688.
14. Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost 2005, 3:2185-2192. 10.1111/j.1538-7836.2005.01274.x, 16194197.
15. Cote F, Thevenot E, Fligny C, Fromes Y, Darmon M, Ripoche MA, Bayard E, Hanoun N, Saurini F, Lechat P, Dandolo L, Hamon M, Mallet J, Vodjdani G. Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function. Proc Natl Acad Sci USA 2003, 100:13525-13530. 10.1073/pnas.2233056100, 263847, 14597720.
16. Lesurtel M, Soll C, Graf R, Clavien PA. Role of serotonin in the hepato-gastroIntestinal tract: an old molecule for new perspectives. Cell Mol Life Sci 2008, 65:940-952. 10.1007/s00018-007-7377-3, 18080089.
17. Russo J, Russo IH. Toward a physiological approach to breast cancer prevention. Cancer Epidemiol Biomarkers Prev 1994, 3:353-364.
18. Mallon E, Osin P, Nasiri N, Blain I, Howard B, Gusterson B. The basic pathology of human breast cancer. J Mammary Gland Biol Neoplasia 2000, 5:139-163. 10.1023/A:1026439204849, 11149570.
19. Marzioni M, Glaser S, Francis H, Marucci L, Benedetti A, Alvaro D, Taffetani S, Ueno Y, Roskams T, Phinizy JL, Venter J, Fava G, Lesage GD, Alpini G. Autocrine/paracrine regulation of the growth of the biliary tree by the neuroendocrine hormone serotonin. Gastroenterology 2005, 128:121-137. 10.1053/j.gastro.2004.10.002, 15633129.
20. Alpini G, Invernizzi P, Gaudio E, Venter J, Kopriva S, Bernuzzi F, Onori P, Franchitto A, Coufal M, Frampton G, Alvaro D, Lee SP, Marzioni M, Benedetti A, DeMorrow S. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res 2008, 68:9184-9193. 10.1158/0008-5472.CAN-08-2133, 2593938, 19010890.
21. Vicentini LM, Cattaneo MG, Fesce R. Evidence for receptor subtype cross-talk in the mitogenic action of serotonin on human small-cell lung carcinoma cells. Eur J Pharmacol 1996, 318:497-504. 10.1016/S0014-2999(96)00812-6, 9016944.
22. Siddiqui EJ, Shabbir M, Mikhailidis DP, Thompson CS, Mumtaz FH. The role of serotonin (5-hydroxytryptamine1A and 1B) receptors in prostate cancer cell proliferation. J Urol 2006, 176:1648-1653. 10.1016/j.juro.2006.06.087, 16952708.
23. Sreevidya CS, Khaskhely NM, Fukunaga A, Khaskina P, Ullrich SE. Inhibition of photocarcinogenesis by platelet-activating factor or serotonin receptor antagonists. Cancer Res 2008, 68:3978-3984. 10.1158/0008-5472.CAN-07-6132, 2394717, 18483284.
24. Suzuki A, Naruse S, Kitagawa M, Ishiguro H, Yoshikawa T, Ko SB, Yamamoto A, Hamada H, Hayakawa T. 5-Hydroxytryptamine Strongly Inhibits Fluid Secretion in Guinea Pig Pancreatic Duct Cells. J Clin Invest 2001, 108:749-756. 209377, 11544281.
25. Nathan JD, Liddle RA. Neurohormonal control of pancreatic exocrine secretion. Curr Opin Gastroenterol 2002, 18:536-544. 10.1097/00001574-200209000-00003, 17033330.
26. Russo F, Vittoria A. Neuroendocrine cells in the vestibular glands of the genital tract of cows and pigs. Acta Histochem 2006, 108:351-355. 10.1016/j.acthis.2006.06.004, 16997356.
27. Ogawa T, Sugidachi A, Tanaka N, Fujimoto K, Fukushige J, Tani Y, Asai F. Effects of R-102444 and its active metabolite R-96544, selective 5-HT2A receptor antagonists, on experimental acute and chronic pancreatitis: Additional evidence for possible involvement of 5-HT2A receptors in the development of experimental pancreatitis. Eur J Pharmacol 6544, 521:156-163. 10.1016/j.ejphar.2005.08.033.
28. Siddiqui EJ, Thompson CS, Mikhailidis DP, Mumtaz FH. The role of serotonin in tumour growth (review). Oncol Rep 2005, 14:1593-1597.
29. Van Lommel A. Pulmonary neuroendocrine cells (PNEC) and neuroepithelial bodies (NEB): chemoreceptors and regulators of lung development. Paediatr Respir Rev 2001, 2:171-176. 10.1053/prrv.2000.0126, 12531066.
30. Ethier SP, Summerfelt RM, Cundiff KC, Asch BB. The influence of growth factors on the proliferative potential of normal and primary breast cancer-derived human breast epithelial cells. Breast Cancer Res Treat 1991, 17:221-230. 10.1007/BF01806371, 1710154.
31. The National Cancer Institute-Cooperative Breast Cancer Tissue. , http://cbctr.nci.nih.gov/
32. Huang Y, Li X, Jiang J, Frank SJ. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells. Oncogene 2006, 25:7565-7576. 10.1038/sj.onc.1209740, 16785991.
33. Tonner E, Barber MC, Travers MT, Logan A, Flint DJ. Hormonal control of insulin-like growth factor-binding protein-5 production in the involuting mammary gland of the rat. Endocrinology 1997, 138:5101-5107. 10.1210/en.138.12.5101, 9389489.
34. McCarty KS, Miller LS, Cox EB, Konrath J, McCarty KS. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985, 109:716-721.
35. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005, 116:340-350. 10.1002/ijc.21004, 15818618.
36. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, Varambally S, Ghosh D, Chinnaiyan AM. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007, 9:166-180. 10.1593/neo.07112, 1813932, 17356713.
37. Oncomine database. , http://www.oncomine.org
38. Nilsson T, Longmore J, Shaw D, Pantev E, Bard JA, Branchek T, Edvinsson L. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 1999, 372:49-56. 10.1016/S0014-2999(99)00114-4, 10374714.
39. Kato S, Kumamoto H, Hirano M, Akiyama H, Kaneko N. Expression of 5-HT2A and 5-HT1B receptor mRNA in blood vessels. Mol Cell Biochem 1999, 199:57-61. 10.1023/A:1006999031932, 10544952.
40. Motyl T, Gajkowska B, Zarzynska J, Gajewska M, Lamparska-Przybysz M. Apoptosis and autophagy in mammary gland remodeling and breast cancer chemotherapy. J Physiol Pharmacol 2006, 57(Suppl 7):17-32.
41. Stein T, Salomonis N, Gusterson BA. Mammary gland involution as a multi-step process. J Mammary Gland Biol Neoplasia 2007, 12:25-35. 10.1007/s10911-007-9035-7, 17431797.
42. Bemis LT, Schedin P. Reproductive state of rat mammary gland stroma modulates human breast cancer cell migration and invasion. Cancer Res 2000, 60:3414-3418.
43. McDaniel SM, Rumer KK, Biroc SL, Metz RP, Singh M, Porter W, Schedin P. Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. Am J Pathol 2006, 168:608-620. 10.2353/ajpath.2006.050677, 1606507, 16436674.
44. Schedin P, O'Brien J, Rudolph M, Stein T, Borges V. Microenvironment of the involuting mammary gland mediates mammary cancer progression. J Mammary Gland Biol Neoplasia 2007, 12:71-82. 10.1007/s10911-007-9039-3, 17318269.
45. Polyak K. Breast cancer: origins and evolution. J Clin Invest 2007, 117:3155-3163. 10.1172/JCI33295, 2045618, 17975657.
46. Howard BA, Gusterson BA. Human breast development. J Mammary Gland Biol Neoplasia 2000, 5:119-137. 10.1023/A:1026487120779, 11149569.
47. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997, 57:4987-4991.
48. Jarzabek K, Koda M, Kozlowski L, Mittre H, Sulkowski S, Kottler ML, Wolczynski S. Distinct mRNA, protein expression patterns and distribution of oestrogen receptors alpha and beta in human primary breast cancer: correlation with proliferation marker Ki-67 and clinicopathological factors. Eur J Cancer 2005, 41:2924-2934. 10.1016/j.ejca.2005.09.010, 16289616.
49. Hewitt SC, Korach KS. Progesterone action and responses in the alphaERKO mouse. Steroids 2000, 65:551-557. 10.1016/S0039-128X(00)00113-6, 11108859.
50. Lange CA. Challenges to defining a role for progesterone in breast cancer. Steroids 2008, 73:914-921. 10.1016/j.steroids.2007.12.023, 2481303, 18243264.
51. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231. 10.1016/j.ccr.2009.01.027, 19249680.
52. Westphal RS, Sanders-Bush E. Differences in agonist-independent and -dependent 5-hydroxytryptamine2C receptor-mediated cell division. Mol Pharmacol 1996, 49:474-480.
53. De Lucchini S, Ori M, Nardini M, Marracci S, Nardi I. Expression of 5-HT2B and 5-HT2C receptor genes is associated with proliferative regions of Xenopus developing brain and eye. Brain Res Mol Brain Res 2003, 115:196-201. 10.1016/S0169-328X(03)00173-6, 12877990.
54. Sonier B, Arseneault M, Lavigne C, Ouellette RJ, Vaillancourt C. The 5-HT2A serotoninergic receptor is expressed in the MCF-7 human breast cancer cell line and reveals a mitogenic effect of serotonin. Biochem Biophys Res Commun 2006, 343:1053-1059. 10.1016/j.bbrc.2006.03.080, 16580628.
55. Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, Gachet C, Bader M, Clavien PA. Platelet-derived serotonin mediates liver regeneration. Science 2006, 312:104-107. 10.1126/science.1123842, 16601191.
56. Bombik BM, Burger MM. c-AMP and the cell cycle: inhibition of growth stimulation. Exp Cell Res 1973, 80:88-94. 10.1016/0014-4827(73)90278-4, 4361349.
57. Burger MM, Bombik BM, Breckenridge BM, Sheppard JR. Growth control and cyclic alterations of cyclic AMP in the cell cycle. Nat New Biol 1972, 239:161-163. 10.1038/239161a0, 4349672.
58. Sheppard JR. Difference in the cyclic adenosine 3',5'-monophosphate levels in normal and transformed cells. Nat New Biol 1972, 236:14-16.
59. Ryan WL, Heidrick ML. Inhibition of cell growth in vitro by adenosine 3',5'-monophosphate. Science 1968, 162:1484-1485. 10.1126/science.162.3861.1484, 4301778.
60. Ryan WL, Heidrick ML. Role of cyclic nucleotides in cancer. Adv Cyclic Nucleotide Res 1974, 4:81-116.
61. Heidrick ML, Ryan WL. Adenosine 3',5'-cyclic monophosphate and contact inhibition. Cancer Res 1971, 31:1313-1315.
62. Birchmeier W. E-cadherin as a tumor (invasion) suppressor gene. Bioessays 1995, 17:97-99. 10.1002/bies.950170203, 7748170.
63. Itoh M, Bissell MJ. The organization of tight junctions in epithelia: implications for mammary gland biology and breast tumorigenesis. J Mammary Gland Biol Neoplasia 2003, 8:449-462. 10.1023/B:JOMG.0000017431.45314.07, 14985640.
64. Hoevel T, Macek R, Mundigl O, Swisshelm K, Kubbies M. Expression and targeting of the tight junction protein CLDN1 in CLDN1-negative human breast tumor cells. J Cell Physiol 2002, 191:60-68. 10.1002/jcp.10076, 11920682.
65. Swisshelm K, Machl A, Planitzer S, Robertson R, Kubbies M, Hosier S. SEMP1, a senescence-associated cDNA isolated from human mammary epithelial cells, is a member of an epithelial membrane protein superfamily. Gene 1999, 226:285-295. 10.1016/S0378-1119(98)00553-8, 9931503.
66. Hoover KB, Liao SY, Bryant PJ. Loss of the tight junction MAGUK ZO-1 in breast cancer: relationship to glandular differentiation and loss of heterozygosity. Am J Pathol 1998, 153:1767-1773. 1866327, 9846967.
67. Chlenski A, Ketels KV, Korovaitseva GI, Talamonti MS, Oyasu R, Scarpelli DG. Organization and expression of the human zo-2 gene (tjp-2) in normal and neoplastic tissues. Biochim Biophys Acta 2000, 1493:319-324.
68. Ho-Tin-Noe B, Goerge T, Cifuni SM, Duerschmied D, Wagner DD. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res 2008, 68:6851-6858. 10.1158/0008-5472.CAN-08-0718, 2547489, 18701510.
69. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 2003, 100:8621-8623. 10.1073/pnas.1633291100, 166359, 12861075.
70. Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL. p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 2002, 115:3193-3206.
71. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008, 135:825-837. 10.1016/j.cell.2008.09.059, 19041748.
72. Bayer H, Muller T, Myrtek D, Sorichter S, Ziegenhagen M, Norgauer J, Zissel G, Idzko M. Serotoninergic receptors on human airway epithelial cells. Am J Respir Cell Mol Biol 2007, 36:85-93. 10.1165/rcmb.2006-0151OC, 16873768.
73. Polyak K. Is breast tumor progression really linear?. Clin Cancer Res 2008, 14:339-341. 10.1158/1078-0432.CCR-07-2188, 18223205.
74. Nowell PC. The clonal evolution of tumor cell populations. Science 1976, 194:23-28. 10.1126/science.959840, 959840.
75. Ginestier C, Wicha MS. Mammary stem cell number as a determinate of breast cancer risk. Breast Cancer Res 2007, 9:109. 10.1186/bcr1741, 2206714, 17688678.
76. Chang CC. Recent translational research: stem cells as the roots of breast cancer. Breast Cancer Res 2006, 8:103. 10.1186/bcr1385, 1413993, 16524453.
77. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006, 9:121-132. 10.1016/j.ccr.2006.01.013, 16473279.
78. Expression Project for Oncology - Breast Samples. , http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2109
79. Yu K, Ganesan K, Miller LD, Tan P. A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors. Clin Cancer Res 2006, 12:3288-3296. 10.1158/1078-0432.CCR-05-1530, 16740749.
80. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, Wong JE, Liu ET, Bergh J, Kuznetsov VA, Miller LD. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006, 66:10292-10301. 10.1158/0008-5472.CAN-05-4414, 17079448.
81. Miller WR, Larionov AA, Renshaw L, Anderson TJ, White S, Murray J, Murray E, Hampton G, Walker JR, Ho S, Krause A, Evans DB, Dixon JM. Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genomics 2007, 17:813-826. 10.1097/FPC.0b013e32820b853a, 17885619.
82. Ginestier C, Cervera N, Finetti P, Esteyries S, Esterni B, Adelaide J, Xerri L, Viens P, Jacquemier J, Charafe-Jauffret E, Chaffanet M, Birnbaum D, Bertucci F. Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin Cancer Res 2006, 12:4533-4544. 10.1158/1078-0432.CCR-05-2339, 16899599.
83. van 't Veer LJ, Dai H, Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536. 10.1038/415530a, 11823860.
84. Chin SF, Teschendorff AE, Marioni JC, Wang Y, Barbosa-Morais NL, Thorne NP, Costa JL, Pinder SE, Wiel MA, Green AR, Ellis IO, Porter PL, Tavare S, Brenton JD, Ylstra B, Caldas C. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol 2007, 8:R215. 10.1186/gb-2007-8-10-r215, 2246289, 17925008.
85. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524. 10.1038/nature03799, 1283098, 16049480.
86. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gomez HL, Hortobagyi GN, Pusztai L. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006, 24:4236-4244. 10.1200/JCO.2006.05.6861, 16896004.
87. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Vijver MJ, Bergh J, Piccart M, Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98:262-272.
88. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
89. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C, . TRANSBIG Consortium Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007, 13:3207-3214. 10.1158/1078-0432.CCR-06-2765, 17545524, TRANSBIG Consortium.
90. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005, 24:4660-4671. 10.1038/sj.onc.1208561, 15897907.
91. Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009. 10.1056/NEJMoa021967, 12490681.
92. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA, Marks JR, Dressman HK, West M, Nevins JR. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439:353-357. 10.1038/nature04296, 16273092.